Table 3.
12-month Follow-Up Clinical Outcomes According to used stent.
| Overall population | IPTW population | |||||||
|---|---|---|---|---|---|---|---|---|
| DP-DES | BP-DES | Unadjusted HR | p value | DP-DES | BP-DES | adjusted HR | p value | |
| n = 374 | n = 246 | 95% CI | n = 498 | n = 491 | 95% CI | |||
| *Target vessel failure | 138 (36.9) | 78 (31.7) | 0.94 (0.69–1.29) | 0.721 | 154 (30.9) | 140 (28.6) | 0.98 (0.77–1.27) | 0.899 |
| All-cause death | 157 (42.0) | 83 (33.7) | 1.26 (0.95–1.67) | 0.103 | 184 (36.7) | 157 (32.0) | 1.12 (0.90–1.40) | 0.296 |
| Cardiac death | 127 (34.0) | 72 (29.3) | 0.81 (0.60–1.11) | 0.190 | 142 (28.5) | 127 (25.9) | 0.82 (0.64–1.05) | 0.121 |
| Myocardial infarction | 9 (2.4) | 6 (2.4) | 0.99 (0.32–3.15) | 0.999 | 6 (1.2) | 9 (1.8) | 0.91 (0.29–2.89) | 0.873 |
| †Stent thrombosis | 5 (1.3) | 4 (1.6) | 0.70 (0.14–3.46) | 0.660 | 6 (1.2) | 7 (1.4) | 0.81 (0.14–2.83) | 0.441 |
| Target vessel revascularization | 6 (1.6) | 3 (1.2) | 1.45 (0.36–5.78) | 0.602 | 7 (1.4) | 9 (1.8) | 0.87 (0.32–2.32) | 0.782 |
| Any revascularization | 12 (3.2) | 9 (3.7) | 0.88 (0.36–2.12) | 0.776 | 16 (3.2) | 29 (5.9) | 0.55 (0.30–1.03) | 0.061 |
| Re-hospitalization due to HF | 21 (5.6) | 13 (5.3) | 1.14 (0.57–2.28) | 0.711 | 26 (5.2) | 22 (4.5) | 1.24 (0.71–2.17) | 0.457 |
Data are n (%).
*Target vessel failure was defined as a composite of cardiac death, myocardial infarction, and target vessel revascularization.
†Definite or probable stent thrombosis.
BP-DES biodegradable polymer drug-eluting stent, CI confidence interval, DP-DES durable polymer drug-eluting stent, HF heart failure, HR hazard ratio, IPTW inverse probability of treatment weighting.